HAYWARD, Calif.--(BUSINESS WIRE)--April 5, 2006--IMPAX Laboratories, Inc. (NASDAQ:IPXL - News) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) for a generic version of SALAGEN® (Pilocarpine Hydrochlorine) 5 and 7.5 mg Tablets. MGI Pharma, Inc. markets SALAGEN Tablets for the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and for the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome. Total brand and generic sales of SALAGEN in the U.S. were $25 million for the 12 months ended December 31, 2005, according to Wolters Kluwer Health. IMPAX's Global Pharmaceuticals division intends to begin marketing this product in the near future.
